BMRN vs NABL · P/E 40, rev $1.76B vs P/E 103, rev $270.6M
Biomarin Pharmaceutical Inc (BMRN) versus N-Able Inc (NABL) — a side-by-side from cached financials, not a winner call.
Biomarin Pharmaceutical Inc (BMRN) is a biotechnology company listed on NASDAQ.
N-Able Inc (NABL) is a information technology services company listed on US.
Latest reported BMRN revenue for 2026-06-30 was $1.76B. Net income was $150.3M. BMRN currently screens at market cap $10.63B and trailing P/E 39.6.
Latest reported NABL revenue for 2026-06-30 was $270.6M. Net income was $77.0K. NABL currently screens at market cap $1.56B and trailing P/E 103.1.
BMRN currently screens at market cap $10.63B and trailing P/E 39.6. NABL currently screens at market cap $1.56B and trailing P/E 103.1.
Not investment advice. Open the BMRN and NABL stock pages for the full models.
Not investment advice.